ADIL Adial Pharmaceuticals
- 1.0600
- -0.0300-2.75%
Adial Pharmaceuticals News
Express News | Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of Ad04 as a Precision Medicine for the Treatment of Alcohol Use Disorder
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
On Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Inter
Express News | Adial Pharmaceuticals Shares Are Trading Higher After the Company Announced That the First Patient Has Been Does in Its Pharmacokinetics Study of AD04 for Alcohol Use Disorder
Express News | Adial Pharmaceuticals Inc - Topline Results Expected in Early Q4 2024
Express News | Adial Pharmaceuticals- Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of Ad04 for Treatment of Alcohol Use Disorder
Express News | Adial Pharmaceuticals Doses First Patient In Pharmacokinetics Study Of AD04 For Treatment Of Alcohol Use Disorder
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Wednesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced that the first patient had been dosed in a pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients.The study is
Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th
GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDA
Express News | Adial Pharmaceuticals Q1 EPS $(2.19) Misses $(0.35) Estimate
Express News | Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Adial Pharmaceuticals Q1 Net Income USD -6.5 Million
10-Q: Quarterly report
Adial Pharmaceuticals Finalizes Separation Agreement With Dr. Johnson
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder
Adial Pharmaceuticals (ADIL) said Monday it has been granted a US patent covering the combination of its proprietary genetic diagnostic and its lead Investigational New Drug AD04 to treat alcohol use
Express News | Adial Pharmaceuticals Granted Key Patent From the United States Patent and Trademark Office
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersAdial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million. NKGen Biotech (NASDAQ:NKGN) shares moved upwa
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL). This patent expands Adial's intellectual property protection
Express News | EXCLUSIVE: Adial Therapeutics Tells Benzinga 'This Patent Expands Adial's Intellectual Property Protection and Covers the Combination of the Company's Proprietary Genetic Diagnostic to Identify Patients With Specific Genotypes
Analysis
Price Target
No Data
